Myocardial ischemia-reperfusion injury （MIRI） is a key complication of reperfusion therapy for ischemic heart disease. Due to its complex pathological mechanism， there is still a lack of targeted drugs and effective interventions in clinical practice. As the core organelle of cell energy metabolism， mitochondria not only undertake the key function of adenosine triphosphate （ATP） synthesis， but also maintain the homeostasis of intracellular environment by regulating ion dynamic balance， oxidative stress response and apoptosis. Mitophagy is an important mechanism to regulate mitochondrial homeostasis. Phosphatase and tensin homolog （PTEN）-induced putative kinase 1 （PINK1）/Parkin signaling pathway， as one of its core pathways， has been proved to have important physiological functions. Mitophagy mediated by PINK1/Parkin signaling pathway can synergistically act on the pathological process of MIRI through the multi-level regulatory mechanism of oxidative stress， calcium homeostasis imbalance and ferroptosis， so as to achieve the prevention and treatment of MIRI by reducing mitochondrial dysfunction and inhibiting programmed cell death. Studies have shown that modern drugs， such as proprotein convertase subtilisin/kexin type 9 （PCSK9） inhibitors， DL-3-n-butylphenylpeptide， and dapagliflozin， active ingredients of traditional Chinese medicine such as phenols， saponins， flavonoids， and anthraquinones， as well as traditional Chinese medicine compounds and preparations such as Tongxinluo capsules， Shuangshen Ningxin capsules， and Qili Qiangxin capsules， can exert myocardial protection by regulating mitophagy mediated by this pathway and multiple targets. This study focuses on the PINK1/Parkin pathway， aiming to provide new ideas and directions for the prevention and treatment of MIRI from the perspective of PINK1/Parkin-mediated mitophagy.